This is the Brand Medication
Each spray contains 50 Aμg of mometasone furoate. INDICATIONS: NASONEX ® is indicated for the treatment of symptoms of intermittent or persistent allergic rhinitis (formerly classified as seasonal or perennial) under the new classification proposed by the guidelines ARIA (Allergic Rhinitis and its Impact on Asthma, for short in English), in adults, adolescents and children from 2 years. In patients with a history of moderate to severe symptoms of intermittent allergic rhinitis, prophylactic treatment is recommended with NASONEX ® for two to four weeks before the anticipated start of the pollen season.
NASONEX ® Nasal Spray is also indicated for the treatment of symptoms associated with acute rhinosinusitis in patients aged 12 years with no symptoms or signs of bacterial infection. It is also indicated as a treatment associated with antibiotic therapy for acute rhinosinusitis boxes of adult and adolescent patients 12 years and older.
NASONEX ® Nasal Spray is indicated for the treatment of symptoms associated with enlarged adenoids in children and adolescents aged 2 years, as nocturnal snoring, nasal congestion, mouth breathing, nasal discharge and postnasal discharge. NASONEX ® Nasal Spray is also indicated for the treatment of nasal polyps and associated symptoms including congestion and hyposmia in patients older than 18 years.